Ligand Pharmaceuticals | LGND - Trade Debtors


Ligand Pharmaceuticals reported $58.1M in Trade Debtors for its fiscal quarter ending in September of 2025.





Trade Debtors Change Date
Agenus USD 22.44M 1.14M Dec/2025
Amgen USD 9.57B 1.08B Dec/2025
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 218.87M 212.05M Dec/2025
Baxter International USD 2.01B 231M Dec/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Enviri Corporation USD 341.34M 27.84M Dec/2025
Gilead Sciences USD 4.91B 182M Dec/2025
GlaxoSmithKline GBP 7.76B 545M Dec/2025
Glaxosmithkline GBP 10.45B 707.81M Dec/2025
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Insmed USD 140.86M 75.6M Dec/2025
Intrexon USD 1.02M 559K Jun/2024
Ionis Pharmaceuticals USD 66M 41.39M Dec/2025
Karyopharm Therapeutics USD 31.78M 6.82M Sep/2024
Ligand Pharmaceuticals USD 58.1M 15.98M Sep/2025
MacroGenics USD 13.37M 55.86M Dec/2025
Merck USD 12.12B 596M Sep/2025
Pacira USD 124.07M 8.8M Dec/2025
Pfizer USD 18.12B 2.02B Sep/2025
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
Sangamo BioSciences USD 581K 110K Jun/2024
Veracyte USD 44.66M 3.17M Dec/2025